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S U M M A R Y
Background: Mannose-binding lectin (MBL) activates the complement system promoting opsonopha-
gocytosis, which could represent an advantage for Mycobacterium leprae, an intracellular pathogen.
Therefore, a single nucleotide polymorphism (SNP) in the MBL2 gene associated with low levels of MBL
could confer protection against the development of leprosy disease.
Methods: In this study, we investigated SNPs of the MBL2 gene and MBL levels in 228 Brazilian leprosy
patients and 232 controls.
Results: There were no differences in the frequencies of variant genotypes and haplotypes of MBL2
between patients and controls, or between the different clinical forms of leprosy. In the group of patients
with a genotype for high expression of MBL2, those aged > 40 years had decreased MBL levels compared
to patients aged 40 years (p = 0.037).
Conclusion: Our results demonstrate that age could inﬂuence the phenotype of MBL2, but no evidence
was found for an association of MBL2 polymorphism with susceptibility to leprosy or its clinical forms.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Leprosy is a chronic infectious disease caused by Mycobacterium
leprae, an intracellular pathogen that infects mainly macrophages
and Schwann cells.1 Most individuals do not develop clinical
manifestations, even after prolonged exposure to M. leprae. Those
who do develop clinical manifestations present four major forms:
tuberculoid, lepromatous, borderline, and indeterminate. The high
degree of clonality in the genome of M. leprae isolates from various
parts of the world,2 suggests that the variability in susceptibility to
infection with the Mycobacterium is largely due to host genetic
factors.3 The single nucleotide polymorphism (SNP) of several
genes that could inﬂuence the variability in susceptibility to
leprosy has been extensively investigated, showing different
results according to the population studied.4–6
Positive or negative associations between leprosy and poly-
morphisms of the immune system molecules have been described,
such as the human leukocyte antigen (HLA),4,7 interleukin 10 (IL-* Corresponding author. Tel.: +55 81 3183 3512; fax: +55 81 3183 3510.
E-mail address: luydson@yahoo.com.br (L.R.S. Vasconcelos).
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doi:10.1016/j.ijid.2011.04.00810),8–10 Toll-like receptor 2 (TLR 2),8 lymphotoxin alpha (LTA),
tumor necrosis factor alpha (TNF-a), receptor for vitamin D (VDR),
receptor for component of the complement system (CR1),8 and
mannose-binding lectin (MBL).8,11,12 These studies have revealed a
great genetic complexity involved in controlling susceptibility to
leprosy and modulation of the clinical spectrum of leprosy in
humans.
MBL is a lectin of the innate immune system that plays an
important role as a pattern recognition molecule in the identiﬁca-
tion of pathogens; it is able to activate the complement system,
promoting phagocytosis and modulation of inﬂammation.13 SNPs
in the MBL gene (MBL2) are responsible for reduced serum levels of
the protein. Three SNPs in the promoter region modulate the
expression of the molecule, of which the alleles are H/L
(position  550), X/Y (position  221), and P/Q (position +4).14
Exon-1 of MBL2 presents allelic variants B (Gly54Asp), C
(Gly57Glu), and D (Arg52Cys), collectively termed allele ‘O’, while
the wild-type allele is called ‘A’. The amino acid changes affect the
oligomerization of variant MBL, which has a lower molecular
weight and is dysfunctional compared to normal MBL; this
inﬂuences the biological activity of the lectin and also reduces
its serum concentration.15ses. Published by Elsevier Ltd. All rights reserved.
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levels of MBL predispose to infection by various pathogens,14,16 as
well as to the development of autoimmunity.17However, genotypes
of low expression of MBL have been associated with protection
against the development of visceral leishmaniasis,18 tuberculosis,19
and leprosy.11 It is suggested that MBL2 may have undergone natural
selection pressures, which induce genetic polymorphisms, resulting
in biological advantages. However, a selective neutrality test with
respect to the complete sequencing of the gene showed signiﬁcant
results only for the population of individuals of European origin, but
not for African-Americans or Hispanics.20 Indeed, a larger study
focusing on evolutionary insights into the high prevalence of MBL2
allele deﬁciency worldwide, supports the idea that the role of MBL is
redundant in human host defense.21
Studies of the association of MBL2 polymorphisms with leprosy
present conﬂicting results. Fitness et al.8 found no association in a
study of the ﬁrst exon variant alleles in leprosy in a population of
paucibacillary patients from the northeast of Africa. In contrast, de
Messias-Reason et al.,11 studying Brazilian patients with leprosy
in the southern region, which has a large European colonization
inﬂuence, showed a positive association between high-expression
haplotypes of MBL2 with susceptibility to leprosy per se, whereas
those with low expression were associated with the tuberculoid
form. In addition, in an Indian population from Nepal, the B variant
allele was present in 4.3% of patients with the tuberculoid vs. 1.5%
of patients with the lepromatous form, however the authors stated
that the statistical signiﬁcance was modest and that more studies
were needed for conclusive validation.12
Due to the complex genetic regulation of susceptibility to
leprosy, the inﬂuence of polymorphism in MBL2 could vary
according to the genetic background of the population studied.
Boldt et al.22 demonstrated that the frequencies of polymorph-
isms of exon-1 and the promoter of MBL2 are different among
Brazilians of different genetic backgrounds. Therefore, this study
aimed to investigate the association of MBL2 polymorphism and
serum levels of MBL in a group of patients with different forms of
leprosy from the northeast of Brazil.
2. Patients and methods
2.1. Patients and controls
We recruited 232 healthy blood donors as the control group and
228 patients with leprosy from the city of Recife, northeast of
Brazil, matched by place of origin. The control group had a mean
age of 33  8.3 years, and 58% of subjects were male. In the leprosy
group, the clinical forms were distributed as follows: 26% leproma-
tous, 31% borderline, 16% tuberculoid, 7% indeterminate, and 20%
were not classiﬁed. The average age of patients was 44.8  16 years,
with 59% male subjects. The classiﬁcation of disease with regard to
the operational class – paucibacillary (PB) and multibacillary (MB) –
was based on the information provided by SINAN (Technical
Information System for Notiﬁable Diseases/Ministry of Health, Brazil,
2008), which uses the Ridley and Jopling classiﬁcation (1966).23
This study was approved by the Research Ethics Committee of
Aggeu Magalha˜es (CEP/CPqAM/Fiocruz, record 45/06). All subjects
in the study signed a consent form.
2.2. DNA extraction and genotyping
DNA samples were extracted from whole blood in anticoagulant
solution (EDTA) using the QIAamp Mini Spin Columns Kit (Qiagen,
Basel, Switzerland) following the manufacturer’s instructions.
The promoter region of MBL2 was genotyped by real-time PCR,
using speciﬁc probes, performed by the TaqMan system. The
probes and validated protocols for the regions  550 and  221 areavailable at http://snp500cancer.nci.nih.gov. For determination
of alleles H/L, the following probes and primers were used:
FAM-MGB-AGCCTGTGTAAAAC, VIC-MGB-CCTGTCTAAAACACC,
CCAACGTAGTAAGAAATTTCCAGAGA-forward, and reverse-CAACC-
CAGCCCAGAATTAACTG. For alleles X/Y, the following probes and
primers were used: FAM-CATGCTTTCCGTGGCAG-MGB, VIC-MGB-
CATGCTTTCGGTGGCAG, GCACGGTCCCATTTGTTCTCA-forward,
and reverse-GCGTTGCTGCTGGAAGACTATAAA.
Genotyping of the structural region (exon-1) of MBL2 was
performed using the technique of real-time PCR with melting
temperature assay (MTA), as described by Hladnik et al.,24 using
the following primers: forward primer 50-AGGCAT-
CAACGGCTTCCCA-30, reverse primer 50-CAGAACAGCCCAACACG-
TACCT-30. The three allelic variants of the MBL2 gene in codon
positions 52, 54, and 57 in exon-1 were designated ‘O’, and the
wild-type allele designated ‘A’.
2.3. MBL serum concentration
The serum concentrations of MBL were determined using a
commercial capture enzyme-linked immunosorbent assay (ELISA;
Antibody Shop, Copenhagen, Denmark). Sera were diluted 1:100
and added to ELISA plates coated with monoclonal antibody
against the binding carbohydrate domain. The bound MBL was
detected by a second biotin-labeled antibody and the streptavidin–
peroxidase system. Tetramethylbenzidine was used as substrate.
Reading of the reaction was performed at 450 nm using an ELISA
plate reader (BioRad, CA, USA). According to the manufacturer, the
concentrations of MBL in normal serum are classiﬁed as low at
levels of < 100 ng/ml, intermediate at 100–1000 ng/ml, and high at
>1000 ng/ml.
2.4. Grouping of genotypes according to serum MBL and haplotypes
Genotypes of the promoter region (550 H/L, 221 X/Y) were
grouped with genotypes of the exon-1 (A/O) and correlated to MBL
serum concentrations in the leprosy patients to categorize groups
of low, intermediate, and high expression.14 The following
genotypes were considered as high expression (total n = 87,
median = 3190 ng/ml): HYA/HYA (n = 22, median = 3063 ng/ml),
HYA/LYA (n = 32, median = 2658 ng/ml), LYA/LYA (n = 33, medi-
an = 3667 ng/ml); intermediate expression (total n = 105, medi-
an = 848 ng/ml): LYA/LXA (n = 19, median = 2121 ng/ml), HYA/LXA
(n = 27, median = 2694 ng/ml), HYA/HYO (n = 6, median = 1805 ng/
ml), HYA/LYO (n = 18, median = 564 ng/ml), LYA/LYO (n = 29,
median = 338 ng/ml), LXA/LXA (n = 6, median = 946 ng/ml); and
low expression (total n = 36, median = 30 ng/ml): HYO/LXA (n = 7,
median = 190 ng/ml), HYO/LYO (n = 6, median = 16 ng/ml), LYO/
LYO (n = 8, median = 20 ng/ml), LXA/LYO (n = 15, median = 59 ng/
ml). The haplotypes were then divided into groups of low (LXA,
HYO, LYO) and high (HYA, LYA) expression of the MBL2 gene.14
2.5. Determination of serum C-reactive protein
C-reactive protein (CRP) levels were used as a marker of
inﬂammation. The exam was performed using the Turbidimetric
Ultra-sensitive CRP Kit (Biotech, Minas Gerais, Brazil), with sample
collection and the test protocol as per the manufacturer’s
instructions, and the results were read on a TARGA 3000 (Rome,
Italy). The reference concentration for CRP indicated by the kit
manufacturer was <3 mg/l.
2.6. Statistical analysis
The Mann–Whitney or Kruskal–Wallis test was employed when
appropriate for comparison of the variation in MBL serum
Table 1
Characterization of leprosy patients (all patients and by clinical form) and controls by gender, age, and serum concentrations of C-reactive protein and mannose-binding
lectin
Group Gender, M/F Age (years), average  SD CRP (mg/l), median (min–max)a MBL (ng/ml), median (min–max)
Control (n = 232) 135/97 33  8.3 ND ND
Lepromatous (n = 60) 43/17 45.2  15.9 0.161 (0.003–4.08) 1.965 (9–10.203)
Borderline (n = 72) 46/26 41.9  15.6 0.177 (0.001–8.88) 1.904 (10–14.713)
Indeterminate (n = 16) 7/9 46.1  15.2 0.156 (0.004–9.24) 1.659 (19–8.478)
Tuberculoid (n = 36) 13/23 44.8  16.0 0.177 (0.007–8.88) 1.675 (0–7.665)
Paucibacillary (n = 67) 25/42b 44.2  16.3 0.180 (0.004–9.24) 1.413 (8–8.478)
Multibacillary (n = 161) 109/52 44.4  16.0 0.182 (0.001–8.88) 1.817 (4–14.713)
All patients (n = 228) 134/94 44.8  16.0 0.177 (0.001–9.24) 1.674 (4–14.674)
M, male; F, female; SD, standard deviation; CRP, C-reactive protein; MBL, mannose-binding lectin; ND, not determined.
a CRP kit reference value < 3.0 mg/l.
b Paucibacillary vs. multibacillary, gender male vs. female: p = 0.00004, odds ratio 3.52, 95% conﬁdence interval 1.86–6.69.
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(version 5.0; San Diego, CA, USA) was used for these analyses. To
verify the Hardy–Weinberg equilibrium and for the construction of
haplotypes we used the program ARLEQUIN (version 3.11;
University of Bern, Switzerland). To test for differences between
cases and controls, the Chi-square test with Yates’ correction was
employed, and odds ratios (OR) with 95% conﬁdence intervals (CI)
were obtained. The estimated power was 92% to analyze the
association of haplotypes. Epi Info (version 6.03; CDC, Atlanta, GA,
USA) was used to calculate p-values and power.
3. Results
There were no differences between the control subjects and
leprosy patients with regard to gender or mean age. There was also
no difference in gender or age with regard to the clinical forms of
leprosy (lepromatous, borderline, tuberculoid, and indeterminate).Table 2
Genotype allele, and haplotype frequencies of MBL2 gene polymorphism in patients w
Control
(n = 232; 464)
Leprosy
(n = 228; 456)
MB
(n = 161; 322)
PB
(n = 67; 13
Promoter (550)
Allele
L 0.67 (310) 0.68 (310) 0.69 (223) 0.65 (87) 
H 0.33 (154) 0.32 (146) 0.31 (99) 0.35 (47) 
Genotype
L/L 0.46 (106) 0.48 (110) 0.50 (81) 0.43 (29) 
H/L 0.42 (98) 0.40 (90) 0.38 (61) 0.43 (29) 
H/H 0.12 (28) 0.12 (28) 0.12 (19) 0.14 (9) 
Promoter (221)
Allele
Y 0.83 (387) 0.82 (376) 0.83 (267) 0.81 (109)
X 0.17 (77) 0.18 (80) 0.17 (55) 0.19 (25) 
Genotype
Y/Y 0.71 (164) 0.67 (154) 0.68 (109) 0.67 (45) 
Y/X 0.25 (59) 0.30 (68) 0.30 (49) 0.28 (19) 
X/X 0.04 (9) 0.03 (6) 0.02 (3) 0.05 (3) 
Exon-1 (52,54,57)
Allele
A 0.80 (372) 0.77 (352) 0.76 (246) 0.80 (107) 
O 0.20 (92) 0.23 (104) 0.24 (76) 0.20 (27) 
Genotype
A/A 0.63 (147) 0.61 (139) 0.60 (96) 0.64 (43) 
A/O 0.34 (78) 0.33 (75) 0.33 (54) 0.31 (21) 
O/O 0.03 (7) 0.06 (14) 0.07 (11) 0.05 (3) 
Haplotype
High expression
HYA 0.31 (142) 0.28 (127) 0.27 (86) 0.31 (41) 
LYA 0.33 (153) 0.32 (146) 0.33 (105) 0.31 (41) 
Low expression
LXA 0.17 (77) 0.18 (80) 0.17 (55) 0.19 (25) 
HYO 0.03 (12) 0.04 (19) 0.04 (13) 0.04 (6) 
LYO 0.17 (80) 0.18 (84) 0.20 (63) 0.16 (21) 
MB, multibacillary; PB, paucibacillary.
a All comparisons were not signiﬁcant; O = B + C + D alleles.There was no difference in age between the operational classes (PB
and MB), however the frequency of male patients was higher in the
group with the multibacillary form compared to the paucibacillary
form (OR 3.52, 95% CI 1.86–6.69; p = 0.00004). The median serum
CRP level of all leprosy patients, as well as those grouped according
to their clinical form or classiﬁed as PB or MB, was under 3 mg/l.
The median MBL serum concentrations in all patients, as well as by
clinical form and operational class, also did not differ (Table 1).
Table 2 shows the allelic and genotypic frequencies of MBL2 in
the control group and leprosy patients. The two groups were in
Hardy–Weinberg equilibrium. There was no statistical difference
between patients and controls for the allele frequencies of
region  550 (H and L) and its genotypes H/H, H/L, and L/L, or
for the promoter region 221 (X and Y) and for genotypes Y/Y, X/Y,
and X/X. Regarding the frequency of the alleles of exon-1 (A and O)
and genotypes A/A, A/O, and O/O, there were also no signiﬁcant
differences.ith leprosy and the control groupa
4)
Lepromatous
(n = 60; 120)
Borderline
(n = 72; 144)
Tuberculoid
(n = 36; 72)
Indeterminate
(n = 16; 32)
0.67 (81) 0.67 (96) 0.63 (45) 0.59 (19)
0.33 (39) 0.33 (48) 0.37 (27) 0.41 (13)
0.47 (28) 0.46 (33) 0.42 (15) 0.37 (6)
0.42 (25) 0.42 (30) 0.42 (15) 0.44 (7)
0.11 (7) 0.12 (9) 0.16 (6) 0.19 (3)
 0.82 (99) 0.83 (120) 0.85 (61) 0.81 (26)
0.18 (21) 0.17 (24) 0.15 (11) 0.19 (6)
0.68 (41) 0.68 (49) 0.69 (25) 0.69 (11)
0.28 (17) 0.31 (22) 0.31 (11) 0.25 (4)
0.03 (2) 0.01 (1) 0 (0) 0.06 (1)
0.77 (93) 0.76 (110) 0.78 (56) 0.78 (25)
0.23 (27) 0.24 (34) 0.22 (16) 0.22 (7)
0.62 (37) 0.60 (43) 0.58 (21) 0.63 (10)
0.32 (19) 0.33 (24) 0.39 (14) 0.31 (5)
0.06 (4) 0.07 (5) 0.03 (1) 0.06 (1)
0.27 (33) 0.30 (43) 0.35 (25) 0.25 (8)
0.32 (39) 0.30 (43) 0.28 (20) 0.34 (11)
0.18 (21) 0.17 (24) 0.15 (11) 0.19 (6)
0.05 (6) 0.03 (5) 0.03 (2) 0.16 (5)
0.18 (21) 0.20 (29) 0.19 (14) 0.06 (2)
Figure 1. Levels of serum mannose-binding lectin (MBL) in patients with leprosy
according to the genotypes of the promoter and exon-1 of the MBL2 gene; Kruskal–
Wallis p < 0.0001. The following genotypes were considered as high expression
(total n = 87, median = 3190 ng/ml): HYA/HYA (n = 22, median = 3063 ng/ml), HYA/
LYA (n = 32, median = 2658 ng/ml), LYA/LYA (n = 33, median = 3667 ng/ml);
intermediate expression (total n = 105, median = 848 ng/ml): LYA/LXA (n = 19,
median = 2121 ng/ml), HYA/LXA (n = 27, median = 2694 ng/ml), HYA/HYO (n = 6,
median = 1805 ng/ml), HYA/LYO (n = 18, median = 564 ng/ml), LYA/LYO (n = 29,
median = 338 ng/ml), LXA/LXA (n = 6, median = 946 ng/ml); and low expression
(total n = 36, median = 30 ng/ml): HYO/LXA (n = 7, median = 190 ng/ml), HYO/LYO
(n = 6, median = 16 ng/ml), LYO/LYO (n = 8, median = 20 ng/ml), LXA/LYO (n = 15,
median = 59 ng/ml). The haplotypes were divided into low (LXA, HYO, LYO) and
high (HYA, LYA) expression of MBL2 gene.14
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serum concentration of MBL, which was statistically signiﬁcant
(p < 0.001). The three categories of genotype, deﬁned as high,
intermediate, and low, were associated with leprosy and its clinical
forms (Table 3). The frequencies of the haplotypes related to high
(HYA, LYA) and low (LXA, HYO, LYO) expression of MBL2 showed no
signiﬁcant associations with the clinical forms of leprosy.
In addition, leprosy patients were divided into levels catego-
rized by the three genotypes of the 221 promoter region and
exon-1, due to their strong inﬂuence on the expression and
oligomerization, respectively, of the protein.14 The genotypes
comprising these groups were associated with the operating
classes PB and MB. The distribution of patients with PB and MB by
genotypes was: YA/YA, n = 26 PB/59 MB; YA/XA, n = 14 PB/33 MB;
XA/XA, n = 4 PB/4 MB; YA/YO, n = 15 PB/38 MB; YO/XA, n = 6 PB/14
MB; YO/YO, n = 2 PB/12 MB. No statistical difference was observed
for any association between PB vs. MB (Figure 2).
Nevertheless, with regard to the serum levels of MBL, a
signiﬁcant difference was observed when patients were divided
into two groups by age: 40 years and >40 years (p = 0.02) (Figure
3A). This difference was also evident for ages 4–20 years
(median = 3717 ng/ml) and 21–30 years (median = 2615 ng/ml)Table 3
Genotype distribution of the MBL2 gene grouped according to the expression of MBL l
Expression with respect to MBL2 genotypes Leprosy N = 228 (%) C
Le
n
High 87 (38) 2
Intermediate 105 (46) 2
Low 36 (16) 9
MBL, mannose-binding lectin.
a Borderline tuberculoid leprosy, borderline borderline leprosy, borderline lepromatou
square test with Yates’ correction was used for statistical analysis.vs. 41–50 years (median = 433 ng/ml); p = 0.0247. The frequency of
genotypes of low, intermediate, and high MBL2 gene expression did
not vary according to age. The median levels of serum MBL,
grouped according to genotypes of low, intermediate, and high
expression of MBL2 demonstrate that patients with high-expres-
sion genotypes aged >40 years had lower MBL serum levels
compared to those aged 40 years (Figure 3B). There was no
difference between gender and serum levels.
4. Discussion
The hypothesis that high serum levels of MBL could facilitate
the uptake of M. leprae by macrophages was proposed for the ﬁrst
time by Garred et al. in 1994.25 In a study conducted in the south
region of Brazil, no difference was found in the median MBL serum
levels between patients with leprosy (n = 191) and a control group
(n = 110), or between the individual clinical forms. However, the
authors showed that the frequency of serum MBL deﬁciency (<100
ng/ml) was higher in patients with the tuberculoid form compared
with the lepromatous one, suggesting that low levels of MBL could
be protective against progression to the lepromatous form.26 The
authors reported that CRP levels were elevated in all the patients.
Increased CRP levels could alter the MBL levels, since the
production of interleukin 6 (IL-6) and growth hormone (GH)
during the inﬂammatory response have been reported to positively
regulate MBL production, even though the increase has been
shown to be discrete.27,28 Therefore, the higher frequency of MBL
deﬁciency in the tuberculoid group of patients in spite of the high
CRP levels, was probably due to genetic restriction.
In the present study the median CRP in the group of patients
with leprosy was 0.177 mg/l, suggesting that the majority of
patients were producing serum MBL at baseline level. Although the
serum levels provide evidence for a genetic deﬁciency of MBL,
studies on the frequencies of polymorphisms in the promoter and
exon-1 regions of MBL2 are important, because the assays for MBL
determination preferentially recognize MBL high oligomers
associated with wild-type MBL alleles, while the low oligomers
found in the serum of individuals with variant alleles are poorly
detected.14,29 Thus, the results of MBL ELISA detection could be
difﬁcult to interpret, mainly because MBL is an opsonin in addition
to its role in complement activation, and the effects of the MBL
variant alleles on this and other functions is poorly understood.30
In this context, our results suggest that oligomerization of MBL in
the serum of patients with different clinical forms of leprosy do not
differ signiﬁcantly. However it has previously been reported that
variants B and D are able to form high oligomers and activate the
complement system with different effectiveness.29 A study of levels
and activity of MBL in patients with leprosy was performed by
Gomes et al., who demonstrated that high levels of MBL and also
complement activity were more frequent in the lepromatous form.31
In the present study the genotypes associated with high,
medium, and low expression of MBL2 did not show different
frequencies between patients and controls or between the clinicalevels in high, medium, and low concentration in patients with leprosy
linical forms
promatous
 = 60 (%)
Borderlinea
n = 72 (%)
Indeterminate
n = 16 (%)
Tuberculoid
n = 36 (%)
3 (38) 25 (35) 6 (37) 15 (42)
8 (47) 37 (51) 8 (50) 15 (42)
 (15) 10 (14) 2 (13) 6 (17)
s leprosy. No association was signiﬁcant for all possible combinations when the Chi-
Figure 2. Mannose-binding lectin (MBL) levels according to genotype at the 221
promoter region and exon-1 of the MBL2 gene in patients with leprosy, according to
operational class: paucibacillary (PB) or multibacillary (MB). Y and A are wild-type
alleles, X and O are mutant alleles.
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who studied 270 paucibacillary leprosy patients vs. 452 controls in
the Republic of Malawi, a country in the northeast of Africa,
showing no association between the genotypes of exon-1 of MBL2
with susceptibility to the disease.
A study in the south region of Brazil,11 investigating the
association of MBL2 polymorphisms at three positions in the
promoter region (H/L, X/Y, and P/Q) and the variant alleles of the
structural region (B, C, and D) in patients with leprosy (n = 264) vs.
controls (n = 214), showed a higher frequency for LYPA (high MBLFigure 3. Serum levels of mannose-binding lectin (MBL) in patients with leprosy and thei
(n = 41), 31–40 (n = 40), 41–50, (n = 56), 51–60 (n = 44), 61–80 (n = 35). Considering a c
Mann–Whitney U-test p = 0.02. (B) Distribution of serum MBL concentration range low, in
The high-expression genotype showed a signiﬁcant difference between age groups; Mexpression) in the leprosy patients and in patients with the
lepromatous forms. These authors also showed that the haplotypes
and genotypes of low MBL expression were associated with
protection from the lepromatous form of leprosy. The lack of
association of the lepromatous form with other MBL high producer
haplotypes such as HYPA in the study by de Messias-Reason
et al.,11 could be explained by the fact that in Amerindians of South
America this haplotype may be associated with lower serum MBL
than is expected.32 This study was complementary to one that
determined MBL levels, which observed a higher frequency of MBL
deﬁciency for the tuberculoid form in the same group of patients,26
supporting the association of MBL and progression to the
lepromatous form in Brazilians from the south region.
One explanation for the differences between the results
observed by de Messias-Reason et al. 11 and those of the present
study may be the variation in composition of haplotypes and
genotypes, since in the present study the genotyping of
untranslated position +4 of the MBL2 gene (alleles P/Q) was not
performed. However, since the inﬂuence of the Q variant on MBL
serum levels is quite small and overlapping,14 the information
possibly obtained from genotyping this allele may not inﬂuence
the association results concerning the frequency of haplotypes and
genotypes with the circulating high oligomers of serum MBL. On
the other hand, the haplotypes and genotypes constructed with the
Q variant may provide additional genetic insights other than the
inﬂuence of this allele on MBL serum levels.
Furthermore, the variant alleles of the structural region of MBL2
in the present study were not individually determined, but were
considered collectively as allele ‘O’, giving a secure approach to the
estimate of MBL levels as suggested by Garred et al.14
Alternatively, important information regarding the allele speciﬁc
genotype could be missing, since the variant alleles seem to
present different biological features besides the simple variation in
high oligomer formation. Studies of the different expression
systems with regard to the features of human recombinant MBL
variants have shown that the D variant allele has relatively normal
carbohydrate binding and complement activation function and
that the allele B is weakly active, while the C variant allele is
inactive in activating the complement.29,33,34 Interestingly, a studyr relationship with age. (A) Serum levels of MBL by age in years 4–20 (n = 12), 21–30
ut-off of age 40 years and >40 years, there was a difference in the levels of MBL;
termediate, and high, according to the MBL2 genotypes and age 40 and >40 years.
ann–Whitney U-test p = 0.037.
L.R.S. Vasconcelos et al. / International Journal of Infectious Diseases 15 (2011) e551–e557e556with a larger number of patients (n = 933) with leprosy from Nepal
showed a weak association only between the genotype BB (G161A)
and the tuberculoid form. However, no association with any
disease form was found for the allelic frequency of the B variant.12
A limitation of our study was the lack of a racial/color
methodology to estimate ancestry. However, this criterion applied
to the Brazilian population brings with it the problem of regional
subjective differences in color perception, and thus could not be
applied with conﬁdence.35 Indeed, a study with a panel of 40
validated ancestry-informative insertion–deletion DNA poly-
morphisms individually estimated the European, African, and
Amerindian ancestry components of 934 self-categorized White,
Brown, or Black Brazilians from the four most populous regions of
the country. This study showed that in all regions investigated, the
European ancestry was predominant, with proportions ranging
from 60.6% in the northeast to 77.7% in the south.35 Based on these
data we could assume that there was most probably a similar
proportion of genetic backgrounds in the studied groups. However,
differences in ethnicity in the groups cannot be discounted.
Therefore, it could be inferred that the differences in ﬁndings
between our study and that of de Messias-Reason et al.11 may be
related to differences in the background populations. While the
present study included a population of different proportions of
those of Black descent, Amerindians, and White Europeans, which
is characteristic of the northeast of Brazil,35 de Messias-Reason et
al. studied a population of predominantly European composition.
In fact, Boldt et al.22 showed a signiﬁcant difference in the
distribution of haplotypes of the MBL2 gene among populations of
African-Brazilians, Euro-Brazilians, and intermingled Brazilians.
This may have implications for the interaction of the MBL2
polymorphism with other genes in the development of the disease.
Ip et al.,36 in their study of 689 Chinese adults, showed a decline
in serum levels of MBL among healthy individuals aged over 40
years. These authors used the same monoclonal antibody that we
used in the present study to detect MBL in the ELISA. In contrast,
Ytting et al.,37 in their study of 348 healthy individuals from
Denmark, employed an immunoﬂuorometric assay using mannan
as ligand for MBL, and found no difference in MBL levels with age.
The decline in MBL levels in our study was signiﬁcant in MBL
higher producers and could be related to changes in the levels of
hormones triiodothyronine/thyroxine (T3/T4) and GH that occur
with age, which seem to have a strong inﬂuence on the production
of MBL.27,28,38
Therefore, age should be considered as an important variable in
studies of MBL deﬁciency determined by MBL immune recognition
ELISA. In previous studies on patients with leprosy, the association of
genotype, serum MBL, and age has not been investigated, hence it is
difﬁcult to make any direct comparisons with our results. Regarding
the association between MBL levels or genotypes with gender, no
difference was found in patients with the different forms of leprosy,
in contrast to the results of Dornelles et al., 26 who showed a
signiﬁcant increase in MBL levels in male over female patients with
leprosy.
A signiﬁcant association between the MB form and male gender
was observed in our study, and may be because women seek more
health services for esthetic reasons, or greater health care, than
men.39 Also, the median MBL levels in MB patients according to
genotyping for 221 (Y/X) and exon-1 (A/O) was slightly higher
compared to PB patients, though this was not signiﬁcant (Figure
2).
This study shows that the MBL2 polymorphism associated with
the detection of high oligomer MBL does not represent a risk factor
for leprosy or for protection against the lepromatous form of the
disease in patients from the northeast of Brazil. Moreover, we
observed that levels of MBL vary with age, particularly after 40
years, in individuals with leprosy who have a high-expressiongenotype for MBL, suggesting that this variable should be taken
into account in future studies regarding MBL immunogenetics.
Finally, the ﬁndings of our study when considered together with
the published reports, stress the importance of genotyping the
structural MBL2 variant alleles individually and the development
of new detection systems for variant MBL.
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